GSK's consumer health unit Haleon off to a rough start
GSK may regret turning down that offer from Unilever.
The pharma giant’s consumer health unit Haleon officially debuted on the London Stock Exchange on Monday — but it did so with a valuation much lower than Unilever’s takeover bid back in January.
Haleon $HLN started trading at 330 pence, but by mid-morning the stock had fallen to around 317 pence. That leaves the company’s market value around £31 billion (roughly $37 billion), far lower than Unilever’s £50 billion ($68 billion) offer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.